Shares of Merck KGaA (NASDAQ:MKGAY) have earned a consensus rating of “Hold” from the nine analysts that are presently covering the stock. One analyst has rated the stock with a sell recommendation, four have given a hold recommendation and four have issued a buy recommendation on the company. The average 12-month price target among analysts that have issued a report on the stock in the last year is $65.00.
Separately, HSBC Holdings plc cut Merck KGaA from a “hold” rating to a “reduce” rating in a report on Friday, April 7th.
Shares of Merck KGaA (NASDAQ:MKGAY) opened at 37.05 on Friday. Merck KGaA has a 12-month low of $30.04 and a 12-month high of $38.11. The company has a market capitalization of $48.37 billion and a P/E ratio of 27.90. The company’s 50 day moving average is $37.10 and its 200 day moving average is $35.59.
Merck KGaA Company Profile
Merck KGaA is a Germany-based company engaged in the pharmaceutical industry. The Company operates through four business segments: Merck Serono; Consumer Health; Merck Millipore, and Performance Materials. Within the Merck Serono division, the Company focuses on therapeutic areas and prescription drugs of chemical and biotechnological origin.
Receive News & Ratings for Merck KGaA Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Merck KGaA and related companies with MarketBeat.com's FREE daily email newsletter.